People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gelesis Holdings, Inc. | — | Pharmaceuticals | Pre-Seed | $576K | $7.9M | 2022 |
David L. Abraham at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David L. Abraham on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Yishai Zohar | 1 | 2 |
| Clayton L. Christopher | 1 | 2 |
| David Pass | 1 | 2 |
| Jane L. Wildman | 1 | 1 |
| Raju L. Kucherlapati | 1 | 1 |
| Elaine L. Chiquette | 1 | 1 |
| Harry L. Leider | 1 | 1 |
| Dominic L. Perks | 1 | 1 |
| Kathryn L. Cavanaugh | 1 | 1 |
| Paul L. Fonteyne | 1 | 1 |
| Elliot L. Maltz | 1 | 1 |
| Alessandro L. Sannino | 1 | 1 |
| Alison L. Bauerlein | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.